Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro
Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro
复制标题
DOI：
10.1046/j.1365-3024.1999.00209.x
复制
发表时间：
1999-03-01
影响因子：
2.2
通讯作者：
Riley, EM
中科院分区：
文献类型：
--
作者：
Egan, AF;Burghaus, P;Riley, EM
恶性疟原虫主要表面蛋白(PfMSP1(19))的19 kDa C末端片段是疟疾亚单位疫苗的候选片段。在这项研究中，我们证明了从疟疾免疫的人血清中纯化的PfMSP1(19)特异性抗体可以：(I)与侵袭抑制单抗竞争与PfMSP1(19)结合；(Ii)在没有补体和单核细胞的情况下，在体外介导抑制寄生虫生长，在生理抗体浓度(100µg/ml)下。表达PfMSP1(19)K1或3D7等位基因的寄生虫对裂殖子入侵的抑制同样敏感，这表明抑制抗体的靶表位是保守的或交叉反应的。这些研究表明，旨在诱导PfMSP1(19)抗体的疫苗可能会预防与临床疾病相关的高水平疟疾寄生虫血症。
The 19kDa, C-terminal fragment of the major surface protein of Plasmodium falciparum (PfMSP1(19)) is a candidate for inclusion in a subunit malaria vaccine. In this study, we show that PfMSP1(19)-specific antibodies, affinity purified from malaria-immune human serum can: (i) compete with invasion-inhibitory monoclonal antibodies for binding to PfMSP1(19) and (ii) mediate inhibition of parasite growth in vitro, in the absence of complement and mononuclear cells, at physiological antibody concentrations (100 mu g/ml). Parasites expressing either the K1 or 3D7 allele of PfMSP1(19) were equally susceptible to inhibition of merozoite invasion, indicating that the target epitopes of inhibitory antibodies are conserved or crossreactive. These studies suggest that vaccines designed to induce antibodies to PfMSP1(19) may protect against the high levels of malaria parasitaemia which are associated with clinical disease.